Brief: Medicus Pharma Receives FDA “Study May Proceed” Letter For NDA-Enabling Registrational Skinject® Study In Patients With Gorlin Syndrome
27/07/2026 14:30
BRIEF-Medicus Pharma Receives FDA “Study May Proceed” Letter For NDA-Enabling Registrational Skinject® Study In Patients With Gorlin Syndrome July 27 (Reuters) - Medicus Pharma Ltd MDCX.O:
MEDICUS PHARMA RECEIVES FDA “STUDY MAY PROCEED” LETTER FOR NDA-ENABLING REGISTRATIONAL SKINJECT® STUDY IN PATIENTS WITH GORLIN SYNDROME
Source text: ID:nGNX5HvJV4
Further company coverage: MDCX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicus Pharma
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Medicus Pharma Submits Optimized Teverelix® Registrational Protocol To FDA To Create Partner Ready Program In Advanced Prostate Cancer